Table 2.

Targeting BCSCs in Clinical Trials.

BCSCs Marker	Agent/Intervention	Study Phase	Clinicaltrials.gov Identifier	Study Status	Type/Stage of Breast Cancer
CD44	Bivatuzumab Mertansine (CD44v6)	I	NCT02254005	Completed	Breast Neoplasms
CD133	Other: Immunohistochemistry Staining Method	N/A	NCT04873154	Recruiting	Breast Cancer
ALDH1	Other: Immunohistochemistry Staining Method and Laboratory Biomarker Analysis	N/A	NCT00949013	Completed	Early-Stage Breast Cancer
	Other: Immunohistochemistry Staining Method and Laboratory Biomarker Analysis	N/A	NCT01424865	Unknown	Breast Cancer
	Doxorubicin-Cyclophosphamide Regimen	N/A	NCT04581967	Recruiting	Breast Cancer
EGFR/HER2	Trastuzumab	N/A	NCT01424865	Unknown	Breast Cancer